Recombinant Products Facility( RPF)
Supporting researchers and industry with collaborative biologics production, purification, training and expertise
Learn More
Research Facility
22 •
Challenge
Researchers and companies struggle to access reliable expertise, facilities and training to produce high-quality proteins or plasmid DNA( pDNA). Scaling up lab processes often leads to reproducibility issues, creating a critical barrier, the‘ valley of death’, that prevents promising discoveries from progressing to commercialisation.
Solution
RPF addresses biomanufacturing, process development and scale-up challenges by providing end-toend support, including production and purification of proteins and pDNA under a Quality Management System certified to ISO 9001, analytics and hands-on training.
Through contracting and collaborative partnerships, it helps researchers and industry overcome reproducibility and‘ valley of death’ barriers. By embedding practical expertise and tailored support into clients’ projects, it accelerates the translation of research and helps discoveries reach patients, markets and tangible health solutions.
Target customers / end-users
• academic researchers( students and post-doc scientists) studying and developing proteins, pDNA and biologics
• biotechnology and pharmaceutical companies
• preclinical and translational research teams needing highquality, reproducible materials and training.
Progress
• accredited under ISO 9001 since 2021
• accredited Provider for Therapeutic Innovations Australia, and trainer for CSL Ltd in downstream processing
• partnership with RNAi at UNSW in pDNA production and training.
6 recent industry collaborations
ISO 9001 Accredited
Therapeutic Innovations Australia provider
Advanced Manufacturing, Materials & Design
The RPF is translating innovation into realworld health and technology outcomes. It produces and purifies biomolecules such as proteins and pDNA, and offers contracting, training and process development to support research and industry. These have applications such as therapeutics, drug screening, diagnostics, biomaterials and synthetic biology.